Condition deep-dive · 6 min read

Sleep apnea — supplement adjuncts to CPAP and behavioural therapy

Updated 2026-05-12 · Reviewed by SupplementScore editors · No sponsorships

Obstructive sleep apnea (OSA) is one of the most common — and most under-diagnosed — chronic medical conditions in adults. The trial-evidenced primary therapies are CPAP (or BiPAP), mandibular advancement devices, positional therapy, weight loss, and (in selected cases) surgical correction. No supplement substitutes for any of these. Supplements come into play for two narrow purposes: addressing comorbid deficiencies that worsen daytime fatigue and cardiovascular risk, and avoiding "sleep aid" supplements that can make untreated OSA more dangerous.

Read this first. If you snore loudly, have witnessed apneas, wake unrefreshed, have daytime sleepiness, or have hypertension that resists treatment, get a sleep study. Untreated moderate-to-severe OSA increases cardiovascular, cerebrovascular, and metabolic risks substantially. Sedative supplements (kava, high-dose valerian, alcohol-containing tinctures, GABA precursors, melatonin at high doses) can worsen apneas by relaxing upper airway muscle tone and blunting arousal responses to hypoxia. Treat the OSA — don't medicate around it.

Supplement adjuncts with a reasonable role

Tier 1 evidence · For the weight-loss intervention that dominates OSA outcomes

Protein supplementation paired with caloric restriction and resistance training

25–40 g whey or plant protein per serving, 2–3× per day; total daily protein 1.2–1.6 g/kg/day

The Sleep AHEAD trial showed structured weight loss of 10%+ reduces AHI (apnea-hypopnea index) substantially in overweight adults with OSA. Adequate protein during caloric restriction preserves lean mass — the goal is fat loss, not muscle loss. Supplemental protein helps hit the daily target.

Tier 2 evidence · Where deficient (common in OSA populations)

Vitamin D3 (to a 25-OH-D target)

Test 25-OH-D and supplement to 30–50 ng/mL; typical maintenance 1,000–2,000 IU/day

Low vitamin D is common in OSA populations and associated with worse symptom burden. Correction modestly improves quality of life and may reduce inflammatory markers. Test and target.

Tier 2 evidence · For cardiovascular risk substrate

Omega-3 (EPA/DHA)

1–2 g EPA+DHA daily with meals; cardiologist input if AFib coexists

OSA elevates cardiovascular risk substantially. Omega-3 supplementation is a reasonable adjunct for the cardiovascular agenda. Use moderate doses (1–2 g/day) — the 2024 review's high-dose AFib signal is particularly relevant in OSA, which is itself an AFib risk factor.

Tier 2 evidence · For comorbid metabolic syndrome

Berberine

500 mg 2–3× daily with meals

OSA frequently coexists with insulin resistance, T2D, and metabolic syndrome. Berberine has trial-supported metabolic benefits relevant to this comorbidity cluster. Coordinate with prescriber if on metformin or other glucose-lowering therapy.

Tier 3 evidence · For daytime alertness adjunct in CPAP-adherent users with residual sleepiness

Caffeine (standardised)

100–200 mg in the morning; avoid past mid-afternoon to protect sleep

For users with CPAP-adherent but residual daytime sleepiness, time-anchored caffeine is a reasonable bridge. Prescription wakefulness-promoting agents (modafinil, solriamfetol, pitolisant) are the evidence-based pharmacological options.

Tier 3 evidence · Magnesium for general sleep maintenance support

Magnesium (glycinate)

200–300 mg elemental magnesium in the evening

Modest support for sleep quality in users with low magnesium status; does not address OSA mechanism. Use as adjunct to CPAP, not as a substitute for it.

Critical caveats — supplements that can WORSEN untreated OSA

Kava — central nervous system depressant; can worsen apneas. Avoid in untreated OSA.
High-dose valerian — sedative effect; reduces upper-airway muscle tone.
GABA precursors and GABAergic agents — same concern as benzodiazepines: sedation can deepen apneas.
Alcohol-containing herbal tinctures — alcohol is the worst sleep-aid choice in OSA — relaxes airway muscles and worsens apneas markedly.
High-dose melatonin (5–10 mg) — sedation effects at high doses can worsen apneas; low-dose (0.3–0.5 mg) for circadian alignment is acceptable but doesn't treat OSA.
Diphenhydramine ("sleep aid" antihistamines) — sedative and anticholinergic effects worsen OSA.
Cannabis / high-dose CBD as a sleep aid — may relax airway muscles and worsen apneas.

The behavioural and medical layer that dominates supplements

CPAP adherence — the single highest-leverage intervention for moderate-to-severe OSA. Get fitting, humidification, and mask refinement right; this is what determines real-world outcomes.
Weight loss — 10% weight loss reduces AHI by approximately 25–30% in overweight users.
Alcohol cessation or moderation — particularly close to bedtime.
Positional therapy — for positional OSA (worse on the back), side-sleeping alone can dramatically reduce AHI.
Smoking cessation — smoking worsens OSA via airway inflammation.
Mandibular advancement devices — alternative for mild-to-moderate OSA or CPAP-intolerant users.
Surgical evaluation — for anatomical contributors (nasal obstruction, tonsillar hypertrophy, retrognathia) in selected users.
Treat comorbid hypothyroidism, acromegaly, and uncontrolled diabetes — reversible contributors.

Practical quick-start. Get diagnosed properly (sleep study). Get fitted for and adherent with CPAP if indicated. Pursue 10% weight loss if overweight — supplemental protein + caloric restriction + resistance training is the framework. Test and correct vitamin D. Add omega-3 at moderate dose for cardiovascular substrate. Avoid sedative supplements that can deepen apneas. For residual daytime sleepiness despite CPAP adherence, discuss prescription wakefulness-promoting agents with sleep medicine.

What to track

CPAP usage data (most modern machines provide a cloud-based adherence portal — hours/night, mask seal, residual AHI). Daytime sleepiness (Epworth scale). Weight and body composition. Blood pressure (often improves on effective CPAP). For comorbid metabolic disease: HbA1c, lipid panel. For cardiovascular: rhythm monitoring if AFib history. 25-OH-D, TSH, ferritin at baseline.